Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mesothelin-Specific CAR T Cells Target Ovarian Cancer.

Cancer research - 1 Jun 2021

Schoutrop Esther, El-Serafi Ibrahim, Poiret Thomas, Zhao Ying, Gultekin Okan, He Rui, Moyano-Galceran Lidia, Carlson Joseph W, Lehti Kaisa, Hassan Moustapha, Magalhaes Isabelle, Mattsson Jonas

Abstract excerpt

New therapeutic options for patients with ovarian cancer are urgently needed. Therefore, we evaluated the efficacy of two second-generation mesothelin (MSLN)-directed CAR T cells in orthotopic mouse models of ovarian cancer. Treatment with CAR T cells expressing an MSLN CAR construct including the CD28 domain (M28z) significantly prolonged survival, but no persistent tumor control was observed. Despite lower...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GPI-Linked Proteins
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Ovarian Neoplasms

Share to Survival Rate

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 33795251
DOI: 10.1158/0008-5472.CAN-20-2701

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mesothelin-Specific CAR T Cells Target Ovarian Cancer.PMID 33795251Read ↗

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacySemantic proximity Read ↗

Ligand-based adoptive T cell targeting CA125 in ovarian cancerSemantic proximity Read ↗

Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.Semantic proximity Read ↗

Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR CircuitsSemantic proximity Read ↗

Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancerSemantic proximity Read ↗

Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachmentSemantic proximity Read ↗

Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian CancerSemantic proximity Read ↗

Immunotherapy for ovarian cancer is improved by tumor-targeted delivery of a neoantigen surrogateSemantic proximity Read ↗

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored ImmunotherapySemantic proximity Read ↗

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.Semantic proximity Read ↗

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.Semantic proximity Read ↗

Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.